Literature DB >> 9085316

Effects of dialysis membrane on intradialytic vancomycin administration.

M K Scott1, W L Macias, M A Kraus, W R Clark, M A Carfagna, B A Mueller.   

Abstract

STUDY
OBJECTIVE: To quantify the influence of hemodialyzers on vancomycin removal when the drug was infused during hemodialysis.
DESIGN: Prospective, controlled, crossover study with three arms.
SETTING: A university-affiliated medical center. PATIENTS: Eight subjects receiving outpatient hemodialysis.
INTERVENTIONS: The three treatment arms were vancomycin 1000 mg infused after dialysis was completed (control), and the same dosages infused during the last hour of hemodialysis with a cellulose triacetate (CT) and a cellulose acetate (CA) hemodialyzer.
MEASUREMENTS AND MAIN RESULTS: The areas under the curve from time zero to 44 hours (AUC0-44 hrs) for the three study arms were significantly different (p < 0.05), with the mean vancomycin AUC0-44 hrs being significantly lower when administered during CT and CA dialysis (73.7% and 87.2% of control; p < 0.05 vs control). The mean vancomycin peak concentration achieved during CT dialysis was significantly lower than for the CA and control arms (20.5, 23.9, 27.0 mg/L, respectively). Forty-four-hour postinfusion concentrations were similarly lower.
CONCLUSION: Clinicians should recognize that the composition of the hemodialyzer significantly influences vancomycin serum concentrations when the drug is administered during hemodialysis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9085316

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  4 in total

1.  Predicting Maintenance Doses of Vancomycin for Hospitalized Patients Undergoing Hemodialysis.

Authors:  Wasim S El Nekidy; Maher M El-Masri; Greg S Umstead; Michelle Dehoorne-Smith
Journal:  Can J Hosp Pharm       Date:  2016-10-31

Review 2.  Drug dosing during intermittent hemodialysis and continuous renal replacement therapy : special considerations in pediatric patients.

Authors:  Michael A Veltri; Alicia M Neu; Barbara A Fivush; Rulan S Parekh; Susan L Furth
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

3.  Intradialytic administration of daptomycin in end stage renal disease patients on hemodialysis.

Authors:  Noha N Salama; Jonathan H Segal; Mariann D Churchwell; Jignesh H Patel; Lihong Gao; Michael Heung; Bruce A Mueller
Journal:  Clin J Am Soc Nephrol       Date:  2009-06-18       Impact factor: 8.237

4.  Determination of vancomycin and gentamicin clearance in an in vitro, closed loop dialysis system.

Authors:  Soo Min Jang; Katie E Cardone; Thomas D Nolin; Darius L Mason; Darren W Grabe
Journal:  BMC Nephrol       Date:  2014-12-20       Impact factor: 2.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.